Chronic itch associated with systemic origin in patients of a multidisciplinary hospital

Authors

  1. Burdenko Main Military Clinical Hospital, Moscow, Russian Federation
  2. Haass Moscow Medical and Social Institute, Moscow, Russian Federation
  3. Sechenov First Moscow State Medical University, Russian Federation

https://doi.org/10.35571/RMSJ.2019.2.005

Share: VK Telegram By e-mail

Full text

Abstract

Introduction. Chronic itch is a frequent symptom of internal diseases and causes a significant decrease in the patients’ quality of life. Objectives were to study the structure of internal diseases that cause chronic itch in patients in a multidisciplinary hospital, and the features of chronic itch in these diseases; to evaluate the effectiveness of various treatment regimens for chronic itch in these diseases; to evaluate the possibility of widespread use in clinical practice of the Numeric Rating Scale for the measuring the se-verity of chronic itch in the initial diagnosis and in the determination the effectiveness of treatment. Patients and Methods. Chronic skin itching was studied in patients with various diseases undergoing inpatient treatment at the Burdenko Main Military Clinical Hospital. The study included 125 patients: 20 (16%) with chronic renal failure, 17 (13.6%) with liver diseases, 24 (19.2%) with myeloproliferative, 32 (25.6%) with lymphoproliferative and 32 (25.6%) endocrine diseases. In-dividual antipruritic therapy was selected for each patient with different systemic pathology, considering diseases that cause itching. Results. The most effective drugs in the treatment of chronic itching in patients with chronic renal failure were sorbents, gabapentin and capsaicin in the form of an ointment or cream, with cholestasis - cholestyramine, ursodeoxycholic acid, rifampicin and tacrolimus in the form of an ointment, with true polycythemia - antihistamines and mast cell inhibitors, with Hodgkin's lymphoma and mycosis fungoides - mast cell inhibitors, gabapentin and ointments with glucocorticosteroid additives, with diabetes mellitus - antihistamines, mast cell inhibitors and external therapy with calamine, menthol, capsaicin and glucocorticosteroids, with hypothyroidism - emollients. In patients with myeloproliferative and lymphoproliferative diseases and hyperthyroidism chronic itching completely disappeared only after effective treatment of the underlying disease. Conclusion. For each form of itching and for each patient individual therapy should be selected. The most effective treatment for chronic skin itching associated with systemic origin is the successful treatment of the underlying disease. The numerical rating scale is a reliable scale for measuring the severity of itching, however, it cannot consider all the complexity and features of itching.

Keywords

Chronic Pruritus, Chronic Itch, Systemic Diseases, Treatment, Numeric Rating Scale

Для цитирования:

Ламоткин И.А., Корабельников Д.И., Ламоткин А.И. Зуд кожный хронический при заболеваниях внутренних органов у больных многопрофильного стационара. Российский медико-социальный журнал. 2019;1(2):57-70. https://doi.org/10.35571/RMSJ.2019.2.005

For citation:

Lamotkin I., Korabelnikov D., Lamotkin A. Chronic itch associated with systemic origin in patients of a multidisciplinary hospital. Russian Medical and Social Journal. 2019;1(2):57-70. (In Russian) https://doi.org/10.35571/RMSJ.2019.2.005

References

  1. Ständer S, Weisshaar E, Mettang T, Szepietowski J, Carstens E, Ikoma A, Bergasa N, Gieler U, Misery L, Wallengren J, Darsow U, Streit M, Metze D, Luger T, Greaves M, Schmelz M, Yosipovitch G, Bernhard J. Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch. Acta Derm Venereol. 2007;87:291-294. doi https://doi.org/10.2340/00015555-0305.
  2. Yosipovitch G, Dawn AG, Greaves MW. Pathophysiology and clinical aspects of itching. In: Fitzpatrick dermatology in clinical practice. [Fitzpatrick TB, Wolff K. Fitzpatrick’s Dermatology in General Medicine. 7th ed. Wolff K, editor. New York: McGraw-Hill Companies; 2008]. Kubanova AA, editor. Adaskevich VP, Gantman MV, translators. Moscow: Publisher Panfilov; BINOM. Laboratory of Knowledge; 2012:985-996. (In Russ.).
  3. Pereira MP, Stander S. Chronic Pruritus: Current and Emerging Treatment Options. Drugs. 2017;77(9):999-1007. doi: https://doi.org/10.1007/s40265-017-0746-9
  4. Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med. 2013;368:1625. doi: https://doi.org/10.1056/NEJMcp1208814
  5. Weisshaar E, Szepietowski JC, Darsow U. et al. European guideline on chronic pruritus. Acta Derm Venereol. 2012;92(5):563-81. doi: https://doi.org/10.2340/00015555-1400
  6. Tarikci N, Kocatürk E, Güngör Ş, Oğuz Topal I, Ülkümen Can P, Singer R. Pruritus in Systemic Diseases: A Review of Etiological Factors and New Treatment Modalities. Sci World J. 2015;2015:1-8. doi https://doi.org/10.1155/2015/803752.
  7. Urbonas A, Schwartz RA, Szepietowski JC. Uremic pruritus-an update. Am J Nephrol. 2001;21:343-350. doi: https://doi.org/10.1159/000046272
  8. Virga G, Visentin I, La Milia V, Bonadonna A. Inflammation and pruritus in hemodialysis patients. Nephrol Dial Transplant. 2002;17:2164-2169. doi: https://doi.org/10.1093/ndt/17.12.2164
  9. Combs SA, Teixeira JP, Germain MJ. Pruritus in kidney disease. Seminars in Nephrology. 2015;35(4):383-391. doi: https://doi.org/10.1016/j.semnephrol.2015.06.009
  10. Khan TM, Aziz A, Suleiman AK. Effectiveness of posthemodialysis administration of pregabalin (75 mg) in treatment resistance uremia pruritus. J Pharmacy and Bioallied Sciences. 2016;8(1):74-76. doi: https://doi.org/10.4103/0975-7406.171736
  11. Tajiri K, Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases. World J Gastroenterol. 2017;23(19):3418-3426. doi: https://doi.org/10.3748/wjg.v23.i19.3418
  12. Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163-2182. doi: https://doi.org/10.2165/00003495-200868150-00006
  13. Kremer AE, Namer B, Bolier R, Fischer MJ, Oude Elferink RP, Beuers U. Pathogenesis and Management of Pruritus in PBC and PSC. Dig Dis. 2015;33(S2):164-175. doi: https://doi.org/10.1159/000440829
  14. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006;130:715-720. doi: https://doi.org/10.1053/j.gastro.2005.12.029
  15. Kuiper EM, Hansen BE, de Vries RA et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136:1281-1287. doi: https://doi.org/10.1053/j.gastro.2009.01.003
  16. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatology. 2004;40:467-474. doi: https://doi.org/10.1002/hep.20336
  17. Lamotkin IA, Rukavitsyn AO, Kristosturova OV. Paraneoplasticheskiy kozhnyy zud pri miyeloproliferativnykh zabolevaniyakh [Paraneoplastic skin itching in myeloproliferative diseas-es]. Voyenno-meditsinskiy zhurnal [Military medical journal]. 2014;335(10):69.
  18. Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. American J Hematology. 2013;88(8):665-9. doi: https://doi.org/10.1002/ajh.23474
  19. Heitkemper T, Hofmann T, Phan, Ständer S. Aquagenic pruritus: associated diseases and clinical pruritus characteristics. J der Deutschen Dermatologischen Gesellschaft. 2010;8(10):797-805. doi: https://doi.org/10.1111/j.1610-0387.2010.07463.x
  20. Abdel-Naser MB, Zaki MS, Vousa MH, et al. Cutaneous mononuclear cells and eosinophils are significantly increased after warm water challenge in pruritic areas of polycythemia vera. J Cutan Pathol. 2007;34:924-9. doi: https://doi.org/10.1111/j.1600-0560.2007.00927.x
  21. Vaa BE, Wolanskyj AP, Roeker L, Pardanani A, Lasho TL, Finke CM, et al. Pruritus in primary myelofibrosis: clinical and laboratory correlates. Am J Hematol. 2012;87(2):136-8. doi: https://doi.org/10.1002/ajh.22215
  22. Lamotkin IA. Opukholi i opukholepodobnyye porazheniya kozhi: Atlas [Tumors and tumor-like lesions of the skin. Atlas]. Moscow: BINOM, Laboratory of Knowledge; 2006.
  23. Lamotkin I.A. Klinicheskaya dermatoonkologiya: atlas [Clinical dermatooncology. Atlas]. Moscow: BINOM, Laboratory of Knowledge, 2011.
  24. Lamotkin IA, Rukavitsyn AO, Kristosturova OV. Paraneoplasticheskiy kozhnyy zud pri limfoproliferativnykh zabolevaniyakh [Paraneoplastic skin itching in lymphoproliferative diseases]. Voyenno-meditsinskiy zhurnal [Military medical journal]. 2016;337(9):59-60.
  25. Lamotkin I.A., Seryakov A.P. Porazheniya kozhi pri limfogranulematoze [Skin lesions in lymphogranulomatosis]. Voyenno-meditsinskiy zhurnal [Military medical journal]. 1999;320(11):34-39.
  26. Lamotkin I.A. Onkodermatologiya. Atlas. Uchebnoye posobiye [Oncodermatology. Atlas]. Moscow: Laboratory of Knowledge; 2017.
  27. Rukavitsyn OA, Pop VP, Ageeva TA, Arkhipova NV, Baykov VV, Lamotkin IA, et al. Gematologiya. Natsional'noye rukovodstvo [Hematology. National leadership]. Moscow: GE-OTAR-Media; 2015.
  28. Rubenstein M, Duvic M. Cutaneous manifestations of Hodgkin's disease. International J of Dermatology. 2006;45(3):251-6. doi: https://doi.org/10.1111/j.1365-4632.2006.02675.x
  29. Bartus CL, Parker SRS. Hodgkin lymphoma presenting as generalized pruritus in an adolescent. Cutis. 2011;87(4):169-172.
  30. Al-Mutairi N, Zaki A, Sharma AK, Al Sheltawi M. Cutaneous manifestations of diabetes mellitus. Med Princ Pract. 2006;15:427-430. doi: https://doi.org/10.1159/000095488
  31. Babakinejad P, Walton S. Diabetes and pruritus. Br J Diabetes. 2016;16:154-155. doi: https://doi.org/10.15277/bjd.2016.095
  32. Etter L, Myers SA. Pruritus in systemic disease: mechanisms and management. Dermatol Clin. 2002;20:459-472. doi: https://doi.org/10.1016/s0733-8635(02)00011-6
  33. Adaskevich V.P. Kozhnyy zud. Dermatologicheskiy i mezhdistsiplinarnyy fenomen [Skin itch. Dermatological and interdisciplinary phenomenon]. Moscow: Publisher Panfilov; BINOM. Laboratory Knowledge; 2014.
  34. Mertsalova IB. Kozhnyy zud [Skin itch]. Lechashchiy vrach [Attending physician]. 2010;10:18.

About the authors

  • Igor Lamotkin, Burdenko Main Military Clinical Hospital, Moscow, Russian Federation

    Burdenko Main Military Clinical Hospital — Dermatovenerology Unit, Head,MD

  • Daniil Korabelnikov, Haass Moscow Medical and Social Institute, Moscow, Russian Federation, Haass Moscow Medical and Social Institute, Moscow, Russian Federation, Haass Moscow Medical and Social Institute, Moscow, Russian Federation

    Haass Moscow Medical and Social Institute, Moscow, Russian Federation — Rector

    Haass Moscow Medical and Social Institute, Moscow, Russian Federation — Dept of Preventive Medicine, Head,MD

    Haass Moscow Medical and Social Institute, Moscow, Russian Federation — Dept of Internal Diseases, Professor

  • Andrey Lamotkin, Sechenov First Moscow State Medical University, Russian Federation

    Sechenov First Moscow State Medical University — Military training center, Cadet

How to Cite

Chronic itch associated with systemic origin in patients of a multidisciplinary hospital. (2019). Russian Medical and Social Journal, 1(2), 57-70. https://doi.org/10.35571/RMSJ.2019.2.005
Views: 33 JATS XML

License

Copyright (c) Russian Medical and Social Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

ISSN (Print) 2658-7726 ISSN (Online) 2658-7718